SEP 3 2026
Priovant Therapeutics — brepocitinib
for dermatomyositis
About
Dermatomyositis is a chronic autoimmune disease that causes skin rashes and progressive muscle weakness, often accompanied by fever, lung inflammation, or sensitivity to light. Brepocitinib blocks two immune system signals (TYK2 and JAK1) that drive inflammation and tissue damage. By quieting these pathways, the drug may reduce both the skin and muscle symptoms that disrupt daily life for people with this condition.
Pivotal trial
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in comparison to placebo, as measured by differences in the Total Improvement Score (TIS)
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on brepocitinib
- Brepocitinib Interest Gains Momentum in Idiopathic Inflammatory Myopathies as Rheumatologists Signal Readiness for Targeted, Steroid-Sparing Therapies - Yahoo Finance Singapore
- How The Roivant Sciences (ROIV) Story Is Shifting After Settlements And Brepocitinib Milestones - Yahoo Finance
- A Look At Roivant Sciences (ROIV) Valuation After Encouraging Phase 2 Brepocitinib Data - Yahoo Finance
- Roivant Sciences: Moderna Settlement, Brepocitinib Support A Long-Term Buy (NASDAQ:ROIV) - Seeking Alpha
- Brepocitinib Demonstrated Improved Skin Disease for Patients With Dermatomyositis - Docwire News